LymphoTrack^® T-Cell Low Positive Control

Minimal Residual Disease (MRD) testing is a valuable tool that allows investigators to study and monitor multiple myeloma (MM), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML) and other hematologic diseases. Recent treatment advances have led to significantly increased clinical response and overall survival, but ultimately most subjects will relapse, driving the need for highly sensitive MRD monitoring. The unparalleled sensitivity of NGS-based MRD testing enables earlier detection of relapse compared to other methods and may provide insights to optimize treatment strategies¹.

When monitoring MRD, a highly sensitive detection method such as NGS-based LymphoTrack facilitates the early detection of lymphoproliferative disease relapse. However, MRD test results are dependent on DNA amounts interrogated, as well as the confidence level of the test. Controls tracking MRD test sensitivity are thus necessary when reporting MRD test results. Designed for MRD testing, the LymphoTrack T-Cell Low Positive Control confirms the sensitivity of a run.

Once specific TR rearrangements have been identified, LymphoTrack assays can be used with the LymphoQuant T-Cell Internal Control along with the LymphoTrack T-Cell Low Positive Control to track these clonotype populations to a sensitivity as low as 10^-6.

¹Cheng et al. J Hematol Onc. (2018) 11:105.

This product is sold FOR RESEARCH USE ONLY; not for use in diagnostic procedures.